Pharmaceuticals - Community Register


Community register of medicinal products for human use


Product information

Invented name: Brilique   
Auth. number : EU/1/10/655
INN : ticagrelor
ATC: Anatomical main group: B - Blood and blood forming organs
Therapeutic subgroup: B01 - Antithrombotic agents
Pharmacological subgroup: B01A - Antithrombotic agents
Chemical subgroup: B01AC - Platelet aggregation inhibitors excluding Heparin
Chemical substance: B01AC24 - Ticagrelor
(See WHO ATC Index)
Indication: for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI])
Marketing Authorisation Holder: AstraZeneca AB
SE-151 85 Södertälje, Sverige

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.


European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
07/12/2010 Centralised - Authorisation EMEA/H/C/1241 (2010)8908 of 03/12/2010
26/10/2011 Centralised - Variation EMEA/H/C/1241/IB/1
Updated with Decision(2012)3294 of 14/05/2012
16/05/2012 Centralised - Variation (2012)3294 of 14/05/2012
26/10/2012 Centralised - Variation EMEA/H/C/1241/WS/292 (2012)7650 of 24/10/2012
25/07/2013 Centralised - Variation EMEA/H/C/1241/II/17
Updated with Decision(2014)4369 of 23/06/2014
21/11/2013 Centralised - Variation EMEA/H/C/1241/II/22
Updated with Decision(2014)4369 of 23/06/2014
25/06/2014 Centralised - Variation (2014)4369 of 23/06/2014